Falls and Physical Inactivity in Patients with Gastrointestinal Cancer and Hand–Foot Syndrome

Hiroko Komatsu¹, Kaori Yagasaki¹, Yasuo Hamamoto², Toru Takebayashi³

¹Faculty of Nursing and Medical Care, Keio University, ²Keio Cancer Center, Keio University School of Medicine, ³Department of Preventive Medicine and Public Health, School of Medicine, Keio University, Tokyo, Japan

Corresponding author: Hiroko Komatsu, PhD, RN
Faculty of Nursing and Medical Care, Keio University, Tokyo, Japan
Tel: 03-5363-3733
E-mail: komah@sfc.keio.ac.jp

Received: December 15, 2017, Accepted: February 08, 2018

ABSTRACT

Objective: This study aims to ascertain the incidence and association of falls and physical inactivity in patients with gastrointestinal cancer and hand–foot syndrome (HFS) after receiving chemotherapy or targeted therapy. Methods: The present cross-sectional study was conducted on 50 outpatients with HFS of Grade 1 or above, according to the National Cancer Institute Common Terminology Criteria for Adverse Events, following the receipt of chemotherapy or targeted therapy for gastrointestinal cancer in Japan between November 2016 and February 2017. For measurement, Dermatology Life Quality Index (DLQI) and the International Physical Activity Questionnaire were used. Data were analyzed by logistic regression analysis. Results: Of the participants, 18% experienced falls and 60% reported physical inactivity. Multivariate logistic regression revealed that the DLQI treatment domain score was the only factor associated with falls (odds ratio [OR] =8.01, 95% confidence interval [CI] =1.27–50.63, P = 0.027). Physical inactivity was associated with DLQI symptom and feeling domain scores (OR = 5.54, 95% CI = 1.26–24.33, P = 0.023) and the with-oxaliplatin or paclitaxel regimen (OR = 3.71, 95% CI = 1.06–13.03, P = 0.041). Conclusions: The results of the present study suggest patients should be informed that HFS is a risk factor for physical inactivity and falls.

Key words: Falls, gastrointestinal cancer, hand–foot skin reaction, hand–foot syndrome, physical activity

Introduction

Hand–foot syndrome (HFS) is a common adverse event of chemotherapy and causes palmar and plantar erythema, edema, and dysesthesia, with pain, swelling, and vesiculation. HFS is classified into two groups:
chemotherapy-related HFS following treatment with 5-fluorouracil, pegylated liposomal doxorubicin, and capecitabine and multikinase inhibitor-related HFS (also referred to as hand–foot skin reaction) following treatment with sorafenib and sunitinib.[1]

HFS is not life-threatening; however, it restricts daily activities,[2] which causes serious impairment of patients’ social functioning and quality of life.[3] Typical HFS symptoms, such as paresthesia, tingling, burning, or painful sensations on the palms of the hands and soles of the feet interfere considerably with even the simplest everyday activities such as walking.[4] Moreover, patients could become physically inactive because of the recommendation to avoid traumatic activity to prevent the manifestation of HFS.[3,5]

Recent studies have reported that chemotherapy-induced peripheral neuropathy (CIPN) symptoms are associated with the risk of falls[6,7] and physical inactivity.[8] Although HFS affects daily activities, the nature of falls and physical inactivity associated with HFS have not been explored thoroughly. Most anticancer agents, including those that lead to HFS, are administered orally at outpatient clinics; therefore, patients have to cope with difficulties in daily living alone during cancer treatment. Falls and physical inactivity have also been associated with reduced quality of life,[9,10] psychological distress,[11,12] and increased health-care costs.[13] Moreover, patients are required to manage not only the side effects of chemotherapy but also the risk of falls and physical inactivity.

We aimed to ascertain the incidence and association of falls and physical inactivity in patients with gastrointestinal cancer and HFS after receiving chemotherapy or targeted therapy.

**Methods**

**Participants and study design**

A cross-sectional study design was adopted, and convenience sampling was used to recruit patients from Keio University Hospital in Tokyo, Japan, which has approximately 1000 beds. The attending physician selected potential participants from their medical records based on the inclusion and exclusion criteria. The researcher explained the research overview and methods to participants during their clinic visit using a written document and obtained their consent. Recruitment began in November 2016 and follow-up assessment was performed in February 2017. The inclusion criteria were as follows: (1) age of 20 years or older; (2) HFS of Grade 1 or above, according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE version 4.0),[14] following the receipt of chemotherapy or targeted therapy (i.e. monotherapy or combination therapy) for gastrointestinal cancer between November 2016 and February 2017; and (3) the ability to provide written informed consent in Japanese. The exclusion criteria were as follows: (1) being deemed unsuitable for participation in the study by an attending physician because of a cognitive or mental disorder present at the time of recruitment; (2) an Eastern Cooperative Oncology Group performance status of Grade 3 or higher; and (3) registered in a clinical trial. Based on the previous studies, the following 6 risk factors for falls in cancer patients were extracted: age, diabetes status, time since last chemotherapy, CIPN symptom, functional impairment, anxiety, and depression.[7,15,16] HFS symptom and grade were added to these variables, and the sample size was calculated as follows: the number of variables (7) \( \times 10 = 70 \) participants. However, the study was conducted in only one research site, and consequently, failed to include 70 participants. Of the 56 potential participants recruited, six were excluded (i.e., three whose HFS had improved, two with a performance status >3, and one who was already registered in a clinical trial). Fifty patients received written and oral explanations regarding the objectives of the study and provided informed consent. Ethical approval was obtained from the Internal Review Boards at the Faculty of Nursing and Medical Care, Keio University (no. 252), and Keio University School of Medicine (no. 20160181). Trial Registration: no. UMIN000024569.

**Instruments for measurement**

**Hand–foot syndrome severity**

The severity of HFS resulting from chemotherapy or targeted therapy was defined according to the clinical grades based on the NCI-CTCAE version 4.0.[14]

**Patient-reported hand–foot syndrome outcomes**

The Dermatology Life Quality Index (DLQI) is a simple, practical scale that was developed in the United Kingdom by Finlay and Khan[17] to measure dermatology-specific health-related quality of life. The questionnaire includes 10 items pertaining to the impact of the disease on the patient over the preceding week, which are divided between the following six domains: symptoms and feelings, daily activities, leisure, work or school, personal relationships, and treatment.[17] The reliability and validity of the Japanese version of the DLQI have been established in patients with acne.[18,19] The phrase, “your skin problem” in the DLQI can be replaced by another phrase based on the target disease; therefore, the present study used the Japanese version of DLQI and included the phrase, “your hand and foot problems.” License ID CUQoL1369 was obtained to use DLQI. Permission was obtained to use the Japanese version of DLQI Institute for Health Outcomes and Process Evaluation research.
Incidence of falls

The participants were asked whether they had experienced any falls since the onset of HFS, and if so, they were instructed to describe the reasons for falls related to HFS. The patients were also asked whether they had experienced any injuries since the onset of HFS.

Physical activity

Physical activity during the preceding week was assessed using the International Physical Activity Questionnaire-Short Form (IPAQ-SF). The Japanese version of IPAQ-SF is in the public domain, and its reliability and validity have been established in Japanese people aged 20 years and older.[20] The IPAQ-SF, which was developed by the International Consensus Group for cross-national assessment, is a seven-item questionnaire that includes the following four activity-related domains: vigorous-intensity physical activity, moderate-intensity physical activity, walking, and sitting.[21] In accordance with the IPAQ guidelines,[22] total Metabolic Equivalent of Task minutes per week was calculated using the following equation: $3.3 \times$ walking $+ 4.0 \times$ moderate-intensity physical activity $+ 8.0 \times$ vigorous-intensity physical activity. Overall physical activity was also evaluated as a categorical variable (i.e. low, moderate, and high) per IPAQ classification.[22] In the current study, participants in the low-IPAQ category were classified as inactive and participants in the moderate- or high-IPAQ categories were classified as active.

Psychological distress

The present study used the Japanese version of the Kessler 6 (K6), which is the public domain and has demonstrated its reliability and validity in Japanese people aged 20 years and older in assessing psychological distress.[23] The K6, which was developed by Kessler et al.,[24] is a widely used screening scale and consists of six items on mental health problems. Respondents' indicate the extent to which they have experienced the following emotions during the preceding 30 days: sadness, nervousness, restlessness, hopelessness, worthlessness, and feeling that everything was an effort. Responses are provided using a five-point scale ranging from 0 (none of the time) to 4 (all of the time), and total scores range from 0 to 24. The optimal cutoff point for K6 is 13 or above for serious mental illness.[25]

Data analysis

Descriptive statistics were performed to analyze the following: history of falls, demographic characteristics, cancer type and treatment, physical activity (measured via the IPAQ-SF), patient-reported HFS outcomes (measured via the DLQI), and psychological distress (measured via the K6). Mann–Whitney U-test and Fisher’s exact tests were used for continuous and categorical data, respectively, to compare demographic characteristics, cancer type and treatment, and health status between participants who had and had not fallen and participants in the IPAQ low (i.e. inactive) and moderate/high (i.e. active) activity categories. Multiple logistic regression was performed to identify factors associated with falls and physical inactivity. A simultaneous variable selection was used in logistic regression. Statistical tests were two-tailed, and the significance level was set to $P < 0.05$. Statistical analyses were performed using SPSS (Version 22.0. IBM Corp., Armonk, NY, USA).

Results

Participant characteristics

In total, 50 patients participated in the study. Participants’ demographic and clinical characteristics at the time of the survey are shown in Table 1. Their mean age was 63.0 (standard deviation [SD] = 12.8) years. Of the 50 participants, 29 (58.0%) were men, 31 (62.0%) had been educated to college level or higher, and approximately half were employed. Twenty (40.0%), 18 (36.0%), and 12 (24.0%) participants were diagnosed with colon and rectal cancer, gastric cancer, and other types of cancer, respectively; of these, 34 (68.0%) participants had Stage IV cancer. In addition, combination therapy was common (37 participants; 74.0%).

Of 13 (26.0%) patients undergoing monotherapy, 8 (16.0%) and 5 (10.0%) received chemotherapeutic drugs (i.e., capecitabine, TS-1 [Tegafur, Gimeracil, Oteracil Potassium], fluorouracil) and targeted therapy (e.g., regorafenib, sunitinib, imatinib), respectively. Of 37 (74.0%) patients undergoing combination therapy, 23 (46.0%) received chemotherapeutic drugs (e.g., XELOX [capecitabine + oxaliplatin], SOX [TS-1 + oxaliplatin], and FOLFOX [leucovorin calcium + fluorouracil + oxaliplatin]), whereas 14 (28.0%) received chemotherapy and targeted therapy (e.g., XELOX + BV [bevacizumab], FOLFIRI [leucovorin calcium + fluorouracil + irinotecan hydrochloride] + BV). Regarding the combination of drugs for peripheral neuropathy, 32 participants (64.0%) followed a with-oxaliplatin or paclitaxel regimen, while 18 (36.0%) followed a without-oxaliplatin or paclitaxel regimen. Hand–foot syndrome status

Overall, 32 (64.0%) and 18 (36.0%) participants were diagnosed with Grade 1 and Grade 2 HFS, respectively [Table 1]. Participants’ mean (SD) total DLQI score was 4.43 (6.03). Among the six individual DLQI domains, “the effect of disease” was reported as ≥1 by
almost two-thirds (36, 72.0%) of the participants in the symptoms and feelings domain and almost half (22, 44.0%) of the participants in the daily activities domain.

**Incidence of falls**

Of the 50 participants, nine (18.0%) had experienced falls since the onset of HFS. Five participants reported falling once, and four, more than three times. The reasons for falls included “because my feet were numb, it was hard to walk,” “I could not hold a handrail (at home),” “I could not lift my feet up,” and “I lost my balance.” None of the participants who fell were injured.

**Physical activity**

Thirty (60.0%), 15 (30.0%), and 5 (10.0%) participants were classified into the low-, moderate-, and high-IPQA physical activity categories, respectively. Therefore, 60.0% of the participants were physically inactive.

**Factors affecting falls and physical inactivity**

Table 1 shows the associations between cancer-related factors and physical inactivity and falls in cancer patients with HFS. CTCAE grading for HFS was not associated with falls or physical inactivity (Grade 2: falls: 33.3% vs. no falls: 36.6%, P > 0.999; 40.0% of inactive participants vs. 30.0% inactive participants vs. 30.0%...
of active participants, \( P = 0.556 \). DLQI scores \( \geq 1 \) in the symptom and feelings domains were significantly associated with inactivity (86.2% of inactive participants vs. 55.0% of active participants, \( P < 0.022 \)), while DLQI treatment domain score >1 was significantly associated with falls (55.6% of fall participants vs. 12.5% of no fall participants, \( P < 0.011 \)). After adjusting for age (<65 years = 0, >65 years = 1) and sex (man = 0, woman = 1), logistic regression analysis showed that scores of >1 in the DLQI symptoms and feelings domain were significantly associated with physical inactivity (odds ratio [OR] = 5.54, 95% confidence interval [CI] = 1.26–24.33, \( P = 0.023 \)). In addition, the with-oxaliplatin or paclitaxel regimen was significantly associated with inactivity [OR = 3.71, 95% CI = 1.06–13.03, \( P = 0.041 \); Table 2]. DLQI treatment domain score was the only variable significantly associated with having fallen [OR = 8.01, 95% CI = 1.27–50.63, \( P = 0.027 \); Table 3].

### Discussion

For patients with HFS symptoms, such as erythema, erosion, and edema, day-to-day activities could contribute to symptom exacerbation, and avoidance of exposure of the hands and feet to heat, trauma, and pressure is essential. Consequently, patients are likely to be physically inactive. The DLQI symptoms and feelings domain includes items on symptoms as well as embarrassment and self-consciousness related to body image. Moreover, the results suggested that patients with HFS were likely to be physically inactive if they were physically and emotionally concerned about skin problems.

Furthermore, physical inactivity was significantly associated with the with-oxaliplatin or paclitaxel regimen. Platinum-based chemotherapies, including oxaliplatin, tend to lead to sensory peripheral neuropathy consisting of numbness, tingling, and paresthesia in the hands and feet, whereas taxane-based chemotherapies, including paclitaxel, cause sensory neuropathy such as paresthesia, numbness, and neuropathic pain in the hands and feet.\(^{[26]}\) Mols et al.\(^{[8]}\) examined the association between physical activity and CIPN in colorectal cancer survivors and found that failure to follow the physical activity guidelines was associated with CIPN. As patients who follow a with-oxaliplatin or paclitaxel regimen could be vulnerable to both neurological and dermatological symptoms in the hands and feet, they could be at increased risk of physical inactivity.

In the current study, 18.0% of the 50 participants had experienced falls. This result was unable to be compared with data from previous research because few studies have focused on the incidence of HFS-related falls. The participants in the current study lost their balance because of numbness, hyperesthesia in the soles of their feet, and inability to hold handrails because of symptoms in the hands, which led to HFS-related falls. As dysesthesia develops not only insoles of the feet but also the palms and fingers,\(^{[27]}\) patients could experience difficulty in holding handrails, which are intended to prevent falls.

Moreover, the DLQI treatment domain score was significantly associated with having fallen. Patients who reported that skin treatment caused a lot of problems (e.g., creating a mess at home or taking up time) were at a high risk of falls. In the prevention and management of HFS, different skin care approaches are required for different symptoms and grades of toxicity.\(^{[28]}\) Peripheral neuropathy may underlie the difficulty in the management of patients with HFS. A cohort study using random sampling by regimen is needed to determine the incidence of peripheral neuropathy and assess the confounding factors of HFS and falls, taking into account peripheral neuropathy in falls and physical inactivity among patients with cancer and HFS.

The current study suggests that HFS is a risk factor for physical inactivity and falls, and patient education regarding HFS is important in the prevention of falls and physical inactivity. Ideally, patients should be educated before initiating anticancer therapy (e.g., advised that patients with numbness and dysesthesia are likely to lose their balance,
which results in falling). In addition, the increased incidence and severity of adverse drug events resulting from novel therapy, such as HFS, has emphasized the significance of dermatological evaluation in patients with cancer.\[^{[39]}\]

Patient-reported outcome instruments, such as the DLQI, should be used in outpatient visits or telephone counseling conducted to assess difficulties involving dermatological problems affecting patients’ daily lives and the continuation of treatment, which are not reflected in the objective assessment of HFS severity, and determine whether these difficulties are risk factors for falls. Moreover, it is important to understand changes in HFS-related body image and determine whether they are associated with physical inactivity. Frequent communication between patients and health-care professionals helps them to understand patients’ recognition of HFS and encourage patients to manage HFS proactively.

### Conclusion

The results of this study showed that physical inactivity and falls occurred in 60.0% and 18.0%, respectively, of patients with gastrointestinal cancer and HFS Grade 1 or above according to the CTCAE. DLQI symptoms and feelings domain score was significantly associated with physical inactivity, while treatment domain score was significantly associated with falls. In addition, the impact of combination therapy should not be overlooked, as the with-oxaliplatin or paclitaxel regimen was also significantly associated with physical inactivity. Moreover, patients should be informed that HFS is a risk factor for physical inability and falls before initiating anticancer therapy.

This study has limitations. The study was conducted at only one research site; hence, the desired sample size was not included. Therefore, the present study could not establish causality in the relationship between physical inactivity and falls in patients with HFS. In addition, recall bias could have occurred in self-reported fall history. Moreover, the generalizability of the results is limited because the participants were cancer patients at a single hospital in Japan. Future studies with prospective study designs should be conducted to determine the causes of physical inactivity and falls while considering various cancer types and therapy regimens.

### Acknowledgment

This work was supported by the Japan Society for the Promotion of Science KAKENHI (A) Grant Number 16H02696.

### Financial support and sponsorship

Nil.

### Conflicts of interest

There are no conflicts of interest.

### References

1. Sibaud V, Dalenc F, Chevreau C, Roché H, Delord JP, Mourey L, et al. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist 2011;16:1469-78.
2. Clark AS, Vahdat LT. Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: Étiologie and emerging therapies. Support Cancer Ther 2004;1:213-8.
3. Chanprapaph K, Rutnin S, Vachiramon V. Multikinase inhibitor-induced hand-foot skin reaction: A Review of clinical presentation, pathogenesis, and management. Am J Clin Dermatol 2016;17:387-402.
4. Autler J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008;144:886-92.
5. Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): Focus on sorafenib and sunitinib. Oncology 2009;77:257-71.
6. Gewandter JS, Fan L, Magnuson A, Mustian K, Peppone L, Heckler C, et al. Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): A University of Rochester CCOP study. Support Care Cancer 2013;21:2059-66.
7. Kolb NA, Smith AG, Singleton JR, Beck SL, Stoddard GJ, Brown S, et al. The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol 2016;73:860-6.
8. Mols F, Beijers AJ, Vreugdenhil G, Verhulst A, Scheep G, Husson O, et al. Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry. J Cancer Surviv 2015;9:512-22.
9. Wildes TM, Depp B, Colditz G, Stark S. Fall-risk prediction in older adults with cancer: An unmet need. Support Care Cancer 2016;24:3681-4.
10. Babatunde OA, Adams SA, Orekoya O, Basen-Engquist K, Steck SE. Effect of physical activity on quality of life as perceived by endometrial cancer survivors: A Systematic review. Int J Gynecol Cancer 2016;26:1727-40.
11. Stone CA, Lawlor PG, Savva GM, Bennett K, Kenny RA. Prospective study of falls and risk factors for falls in adults with advanced cancer. J Clin Oncol 2012;30:2128-33.
12. Spoelstra S, Given B, von Eye A, Given C. Falls in the community-dwelling elderly with a history of cancer. Cancer Nurs 2010;33:149-55.
13. Bielemann RM, Silva BG, Coll Cde V, Xavier MO, Silva SG. Burden of physical inactivity and hospitalization costs due to chronic diseases. Rev Saúde Pública 2015;49 pii: S0034-89102015000100307.
14. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Available from: http://www.ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40. [Last accessed on 2017 Nov 01].
15. Gewandter JS, Fan L, Magnuson A, Mustian K, Peppone L, Heckler C, et al. Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): A University of Rochester CCOP study. Support Care Cancer 2013;21:2059-66.
16. Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ, et al. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: Prevalence, risk factors, and fall risk. Breast Cancer Res Treat 2016;159:327-33.
17. Finlay AY, Khan GK. Dermatology life quality index (DLQI) – A simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6.
18. Takahashi N, Suzukamo Y, Nakamura M, Miyachi Y, Green J, Ohya Y, et al. Japanese version of the dermatology life quality index: Validity and reliability in patients with acne. Health Qual Life Outcomes 2006;4:46.
19. Fukuhara S. Meaning HRQOL of Patients with Skin Disease Manual of DLQI and Skindex 29 Japanese Version. Tokyo: Shorinsha; 2004.
20. Murase N, Katsumura T, Ueda C, Inoue S, Shimomitsu T. Validity and reliability of Japanese version of international physical activity questionnaire. J Health Welf Stat 2002:49:1-9.
21. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003:35:1381-95.
22. Guidelines for data Processing and Analysis of the International Physical Activity Questionnaire (IPAQ) – Short and Long Forms 2005. Available from: https://www.docsgoogle.com/viewer?a=v&pid=sites&srcid=ZGVmYXVsdGRvbWFpbxbGVPcGFxFxGd4OjE0NGdxMDk3NDU1YWRIZTM. [Last accessed on 2017 Nov 01].
23. Furukawa TA, Kawakami N, Saitoh M, Ono Y, Nakane Y, Nakamura Y, et al. The performance of the Japanese version of the K6 and K10 in the world mental health survey japan. Int J Methods Psychiatr Res 2008;17:152-8.
24. Kessler RC, Andrews G, Colpe LJ, Hiripi E, Mroczek DK, Normand SL, et al. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med 2002;32:959-76.
25. Kessler RC, Barker PR, Colpe LJ, Epstein JF, Groer JC, Hiripi E, et al. Screening for serious mental illness in the general population. Arch Gen Psychiatry 2003;60:184-9.
26. Brewer JR, Morrison G, Dolan ME, Fleming GF. Chemotherapy-induced peripheral neuropathy: Current status and progress. Gynecol Oncol 2016;146:176-83.
27. Lou Y, Wang Q, Zheng J, Hu H, Liu L, Hong D, et al. Possible pathways of capecitabine-induced hand-foot syndrome. Chem Res Toxicol 2016;29:1591-601.
28. De Wit M, Boers-Doets CB, Saettini A, Vermeersch K, de Juan CR, Ouwerkerk J, et al. Prevention and management of adverse events related to sorafenib. Support Care Cancer 2014;22:837-46.
29. Chan A, Cameron MC, Garden B, Boers-Doets CB, Schindler K, Epstein JB, et al. A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. Support Care Cancer 2015;23:2231-44.